

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/724,983
Filing Date	November 28, 2000
First Named Inventor	Scott A. Waldman
Art Unit	1842
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/L.Y./	1	Alexander et al., "Oncogene Alterations in Rat Colon tumors Induced by--methyl-N-nitrosourea," Am. J. Med. Sci. (1992) 303(1):16-24.	
	2	Carrithers et al., "Escherichia coli heat-stable toxin receptors in human colonic tumors," Gastroenterology (1994) 107:1653-1661.	
	3	Bold et al., "Experimental Gene Therapy of Human Colon Cancer," Surgery (1994) 116(2):189-196.	
	4	Carrithers et al., "Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues," Proc Natl Acad Sci USA (1996) 93:14827-14832.	
	5	Takekawa et al., "Chromosomal Localization to the Protein Tyrosine Phosphatase G1 Gene and Characterization of the Aberrant Transcripts in Human Colon Cancer Cells," FEBS Letters (1994) 339(3):222-228.	
	6	Ciardiello et al., "Inhibition of CRFPTO Expression and Tumorigenicity in Human Colon Cancer Cells by Antisense RNA and Oligodeoxynucleotides," Oncogene (1994) 9(1):291-298.	
	7	Collins et al., "C-myc Antisense Oligonucleotides Inhibit the Colony-forming Capacity of Colo 320 Colonic Carcinoma Cells," J. Clin. Investigation (1992) 89(5):1523-1527.	
	8	Cooney et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro," Science (1988) 241:456-459.	
	9	Toribara et al., "Screening for Colorectal Cancer," New England J. Med. (1995) 332:861-867	
	10	Wilson, "Cytotoxicity and viability assays," Animal Cell Culture: A Practical Approach, Freshney, R.I. (Ed.), IRL Press, Oxford (1986) 186-216.	
✓	11	Forte et al., "Guanylin: a Peptide Regulator of Epithelial Transport," The FASEB Journal (1995) 9:643-650.	

Examiner Signature	/Lei Yao/	Date Considered	/Lei Yao/
--------------------	-----------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

## **Complete if Known**

Application Number	09/724,983
Filing Date	November 28, 2000
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/L.Y./	12	Tanaka et al., "Suppression of Tumorigenicity in Human Colon Carcinoma Cells by Introduction of Normal Chromosome 1p36 Region," <i>Oncogene</i> (1993) 8(8):2253-2258.	
	13	Helene et al., "Specific Regulation of Gene Expression by Antisense, Sense and Antigene Nucleic Acids," <i>Biochem. Biophys. Acta</i> (1990) 1049:99-125.	
	14	Urbanski et al., "Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells", <i>Biochim. Et Biophys. Acta</i> , 1995, 1245, 29-36.	
	15	Kent and Clark-Lewis in <i>Synthetic Peptides in Biology and Medicine</i> , pp. 29-57, Alitalo et al., eds, Science Publishers, Amsterdam (1985).	
	16	Yokozaki et al., "An Antisense Oligodeoxynucleotide that Depletes RI Alpha Subunit of Cyclic AMP-dependent Protein Kinase Induces Growth Inhibition in Human Cancer Cells," <i>Cancer Research</i> (1993) 53(4):868-872.	
	17	Knyazev, P.G. et al., "Complex Characteristics of the Alterations of Oncogenes HER-2/ERBB-2, HER-1/ERBB-1, HRAS-1, C-MYC and Anti-Oncogenes p53, RB1, as well as Deletions of Loci of Chromosome 17 in Colon Carcinoma," <i>Molekuliarnaia Biologiya</i> (1992) 26(5):1134-1147 (English translation of title).	
	18	Krause et al., "Autoradiographic demonstration of specific binding sites for E. coli enterotoxin in various epithelia of the North American opossum," <i>Cell Tissue Res</i> (1990) 260(2):387-394.	
	19	Melani et al., "Inhibition of Proliferation by c-myc Antisense Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines that Express c-myc," <i>Cancer Res.</i> (1991) 51(1):2897-2901.	
	20	Nielsen et al., "Sequence-specific Transcription Arrest by Peptide Nucleic Acid Bound to the DNA Template Strand," <i>Gene</i> (1994) 149:139-145.	
	21	Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," pp. 1-42, Dec. 1995.	
	22	White et al., "Opossum kidney contains a functional receptor for the Escherichia. coli heat-stable enterotoxin," <i>Biochemical &amp; Biophysical Res Comm</i> (1989) 159(1):363-367.	
	23	Ramsay et al., "Myb Expression is Higher in Malignant Human Colonic Carcinoma and Premalignant Adenomatous Polyps than in Normal Mucosa", <i>Cell Growth &amp; Differentiation</i> (1992) 3(10):723-30.	

Examiner Signature	/Lei Yao/	Date Considered	05/06/2009
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

## **Complete if Known**

Application Number	09/724,983
Filing Date	November 28, 2000
First Named Inventor	Scott A. Waldman
Art Unit	1642
Examiner Name	Lei Yao
Attorney Docket Number	100051.10161

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/L.Y./	24	Rodriguez-Alfageme et al., "Suppression of Deregulated c-MYC Expression in Human Colon Carcinoma Cells by Chromosome 5 Transfer," PNAS USA (1992) 89(4):1482-1486.	
/L.Y./	25	Sizeland et al., "Antisense Transforming Growth Factor Alpha Oligonucleotides Inhibit Autocrine Stimulated Proliferation of a Colon Carcinoma Cell Line," Mol. Biol. Cell (1992) 3(11):1235-1243.	
/L.Y./	26	Cohen et al., "A gradient in expression of the Escherichia coli heat-stable enterotoxin receptor exists along the villus-to-crypt axis of rat small intestine," Biochemical and Biophysical Research Communications (1992) 186(1):483-490.	

Examiner Signature	/Lei Yao/	Date Considered	05/06/2009
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.